Mostrar el registro sencillo del ítem

Artículo

dc.creatorBorrego Sánchez de la Cuesta, Lorenzo Gabrieles
dc.creatorRecio Jiménez, Rocíoes
dc.creatorMoreno Rodríguez, Nazaretes
dc.creatorChelouan, Ahmedes
dc.creatorÁlvarez, Eleuterioes
dc.creatorSánchez Coronilla, Antonioes
dc.creatorCaro Salazar, Carloses
dc.creatorPearson, John R.es
dc.creatorGarcía-Martín, María Luisaes
dc.creatorKhiar, Noureddinees
dc.creatorFernández Fernández, Inmaculadaes
dc.date.accessioned2023-05-12T14:28:52Z
dc.date.available2023-05-12T14:28:52Z
dc.date.issued2022
dc.identifier.citationBorrego Sánchez de la Cuesta, L.G., Recio Jiménez, R., Moreno Rodríguez, N., Chelouan, A., Álvarez, E., Sánchez Coronilla, A.,...,Fernández Fernández, I. (2022). Enantioselective synthesis of 4-amino-3,4-dihydrocoumarins and their non-cyclic hydroxyester precursors: Biological evaluation for the treatment of glioblastoma multiforme. European Journal of Medicinal Chemistry, 243. https://doi.org/10.1016/j.ejmech.2022.114730.
dc.identifier.issn0223-5234es
dc.identifier.issn1768-3254es
dc.identifier.urihttps://hdl.handle.net/11441/145962
dc.description.abstractThe stereoselective addition of ethyl acetate enolate to the C═N bond of N-tert-butylsulfinylimines has been investigated in depth. A significant effect of the LHMDS amount and the N-sulfinylimine nature on the stereoselectivity of the process was observed. Conditions were found where sulfinylimines of differently substituted salicylaldehydes derivatives, ethyl acetate, and LHMDS afforded the corresponding addition products as a single diastereomer in good yields. The developed protocol was successfully applied to the first stereoselective synthesis of differently substituted 4-amino-3,4-dihydrocoumarin derivatives. Computational models confirmed the prominent role of the ortho aryl substituent in the stereoselectivity of the process. A significant and selective cytotoxic activity against Glioblastoma Multiforme (GBM) cancer line has been determined for the noncyclic hydroxy ester derivative.es
dc.description.sponsorshipMinisterio de Ciencia e Innovación PID2019-104767RB-I00es
dc.description.sponsorshipJunta de Andalucía US- 1381590, FQM-106es
dc.formatapplication/pdfes
dc.format.extent17 p.es
dc.language.isoenges
dc.publisherElsevieres
dc.relation.ispartofEuropean Journal of Medicinal Chemistry, 243.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEnantiopure 4-amino-3,4-dihydrocoumarinses
dc.subjectGlioblastoma multiformees
dc.subjectN-sulfinylarylimineses
dc.subjectβ-hydroxyesterses
dc.titleEnantioselective synthesis of 4-amino-3,4-dihydrocoumarins and their non-cyclic hydroxyester precursors: Biological evaluation for the treatment of glioblastoma multiformees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química Orgánica y Farmacéuticaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química Físicaes
dc.relation.projectIDPID2019-104767RB-I00es
dc.relation.projectIDUS-1381590es
dc.relation.projectIDFQM-106es
dc.relation.publisherversionhttps://doi.org/10.1016/j.ejmech.2022.114730es
dc.identifier.doi10.1016/j.ejmech.2022.114730es
dc.journaltitleEuropean Journal of Medicinal Chemistryes
dc.publication.volumen243es
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (MICINN). Españaes
dc.contributor.funderJunta de Andalucíaes
dc.description.awardwinningPremio Mensual Publicación Científica Destacada de la US. Facultad de Farmacia

FicherosTamañoFormatoVerDescripción
Enantioselective synthesis of 4.pdf6.255MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional